PURPOSE: Imaging plays a crucial role in ablative therapies for prostate cancer (PCa). Irreversible electroporation (IRE) is a new treatment modality used for focal treatment of PCa. We aimed to demonstrate what imaging modalities can be used by descriptively reporting contrast-enhanced ultrasonography (CEUS), multiparametric magnetic resonance imaging (mpMRI), and grey-scale transrectal ultrasound (TRUS) results. Furthermore, we aimed to correlate quantitatively the ablation zone seen on mpMRI and CEUS with treatment planning to provide therapy feedback. METHODS: Imaging data was obtained from two prospective multicenter trials on IRE for localized low- to intermediate-risk PCa. The ablation zone volume (AZV) seen on mpMRI and CEUS was 3D reconstructed to correlate with the planned AZV. RESULTS: Descriptive examples are provided using mpMRI, TRUS, and CEUS for treatment planning and follow-up after IRE. The mean AZV on T2-weighted imaging 4 weeks following IRE was 12.9 cm3 (standard deviation [SD]=7.0), 5.3 times larger than the planned AZV. Linear regression showed a positive correlation (r=0.76, P = 0.002). For CEUS the mean AZV was 20.7 cm3 (SD=8.7), 8.5 times larger than the planned AZV with a strong positive correlation (r=0.93, P = 0.001). Prostate volume is reduced over time (mean= -27.5%, SD=11.9%) due to ablation zone fibrosis and deformation, illustrated by 3D reconstruction. CONCLUSION: The role of imaging in conjunction with IRE is of crucial importance to guide clinicians throughout the treatment protocol. CEUS and mpMRI may provide essential treatment feedback by visualizing the ablation zone dimensions and volume.
PURPOSE: Imaging plays a crucial role in ablative therapies for prostate cancer (PCa). Irreversible electroporation (IRE) is a new treatment modality used for focal treatment of PCa. We aimed to demonstrate what imaging modalities can be used by descriptively reporting contrast-enhanced ultrasonography (CEUS), multiparametric magnetic resonance imaging (mpMRI), and grey-scale transrectal ultrasound (TRUS) results. Furthermore, we aimed to correlate quantitatively the ablation zone seen on mpMRI and CEUS with treatment planning to provide therapy feedback. METHODS: Imaging data was obtained from two prospective multicenter trials on IRE for localized low- to intermediate-risk PCa. The ablation zone volume (AZV) seen on mpMRI and CEUS was 3D reconstructed to correlate with the planned AZV. RESULTS: Descriptive examples are provided using mpMRI, TRUS, and CEUS for treatment planning and follow-up after IRE. The mean AZV on T2-weighted imaging 4 weeks following IRE was 12.9 cm3 (standard deviation [SD]=7.0), 5.3 times larger than the planned AZV. Linear regression showed a positive correlation (r=0.76, P = 0.002). For CEUS the mean AZV was 20.7 cm3 (SD=8.7), 8.5 times larger than the planned AZV with a strong positive correlation (r=0.93, P = 0.001). Prostate volume is reduced over time (mean= -27.5%, SD=11.9%) due to ablation zone fibrosis and deformation, illustrated by 3D reconstruction. CONCLUSION: The role of imaging in conjunction with IRE is of crucial importance to guide clinicians throughout the treatment protocol. CEUS and mpMRI may provide essential treatment feedback by visualizing the ablation zone dimensions and volume.
Authors: Robert E Neal; Jeremy L Millar; Helen Kavnoudias; Peter Royce; Franklin Rosenfeldt; Alan Pham; Ryan Smith; Rafael V Davalos; Kenneth R Thomson Journal: Prostate Date: 2014-01-17 Impact factor: 4.104
Authors: Jelle O Barentsz; Jeffrey C Weinreb; Sadhna Verma; Harriet C Thoeny; Clare M Tempany; Faina Shtern; Anwar R Padhani; Daniel Margolis; Katarzyna J Macura; Masoom A Haider; Francois Cornud; Peter L Choyke Journal: Eur Urol Date: 2015-09-08 Impact factor: 20.096
Authors: F Ting; M Tran; M Böhm; A Siriwardana; P J Van Leeuwen; A M Haynes; W Delprado; R Shnier; P D Stricker Journal: Prostate Cancer Prostatic Dis Date: 2015-10-13 Impact factor: 5.554
Authors: W van den Bos; R R Jurhill; D M de Bruin; C D Savci-Heijink; A W Postema; P G K Wagstaff; B G Muller; I M Varkarakis; A Skolarikos; P J Zondervan; M P Laguna Pes; T M de Reijke; J J M C H de la Rosette Journal: J Urol Date: 2016-03-19 Impact factor: 7.450
Authors: M J Scheltema; K J Tay; A W Postema; D M de Bruin; J Feller; J J Futterer; A K George; R T Gupta; F Kahmann; C Kastner; M P Laguna; S Natarajan; S Rais-Bahrami; A R Rastinehad; T M de Reijke; G Salomon; N Stone; R van Velthoven; R Villani; A Villers; J Walz; T J Polascik; J J M C H de la Rosette Journal: World J Urol Date: 2016-09-16 Impact factor: 4.226
Authors: Willemien van den Bos; Berrend G Muller; Hashim Ahmed; Chris H Bangma; Eric Barret; Sebastien Crouzet; Scott E Eggener; Inderbir S Gill; Steven Joniau; Gyoergy Kovacs; Sascha Pahernik; Jean J de la Rosette; Olivier Rouvière; Georg Salomon; John F Ward; Peter T Scardino Journal: Eur Urol Date: 2014-01-13 Impact factor: 20.096
Authors: Willemien van den Bos; D M de Bruin; A van Randen; M R W Engelbrecht; A W Postema; B G Muller; I M Varkarakis; A Skolarikos; C D Savci-Heijink; R R Jurhill; P J Zondervan; M P Laguna Pes; H Wijkstra; T M de Reijke; J J M C H de la Rosette Journal: Eur Radiol Date: 2015-10-08 Impact factor: 5.315
Authors: Matthijs J Scheltema; John I Chang; Willemien van den Bos; Ilan Gielchinsky; Tuan V Nguyen; Theo de M Reijke; Amila R Siriwardana; Maret Böhm; Jean J de la Rosette; Phillip D Stricker Journal: Diagn Interv Radiol Date: 2018-09 Impact factor: 2.630
Authors: Mara Buijs; Daniel M de Bruin; Peter Gk Wagstaff; Patricia J Zondervan; Matthijs JV Scheltema; Marc W Engelbrecht; Maria P Laguna; Krijn P van Lienden Journal: Diagn Interv Radiol Date: 2021-09 Impact factor: 2.630
Authors: Jonathan B Bloom; Samuel A Gold; Graham R Hale; Kareem N Rayn; Vikram K Sabarwal; Ivane Bakhutashvili; Vladimir Valera; Baris Turkbey; Peter A Pinto; Bradford J Wood Journal: Gland Surg Date: 2018-04
Authors: Matthijs J Scheltema; Tim J O'Brien; Willemien van den Bos; Daniel M de Bruin; Rafael V Davalos; Cees W M van den Geld; Maria P Laguna; Robert E Neal; Ioannis M Varkarakis; Andreas Skolarikos; Phillip D Stricker; Theo M de Reijke; Christopher B Arena; Jean de la Rosette Journal: Ther Adv Urol Date: 2019-06-07
Authors: Veronica M Ringel-Scaia; Natalie Beitel-White; Melvin F Lorenzo; Rebecca M Brock; Kathleen E Huie; Sheryl Coutermarsh-Ott; Kristin Eden; Dylan K McDaniel; Scott S Verbridge; John H Rossmeisl; Kenneth J Oestreich; Rafael V Davalos; Irving C Allen Journal: EBioMedicine Date: 2019-05-23 Impact factor: 8.143